Immunovant, Inc.
IMVT
$14.06
-$1.16-7.62%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | -111.12M | -109.12M | -87.15M | -75.32M | -51.42M |
| Total Depreciation and Amortization | 99.00K | 89.00K | 80.00K | 64.00K | 58.00K |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 11.68M | 12.72M | 13.52M | 9.93M | 10.52M |
| Change in Net Operating Assets | -1.04M | 7.67M | -2.65M | 5.63M | -6.25M |
| Cash from Operations | -100.39M | -88.65M | -76.20M | -59.70M | -47.10M |
| Capital Expenditure | -180.00K | -196.00K | -182.00K | -150.00K | -131.00K |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -180.00K | -196.00K | -182.00K | -150.00K | -131.00K |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 2.46M | 730.00K | 686.00K | 1.55M | 475.86M |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | 0.00 | -6.01M |
| Cash from Financing | 2.46M | 730.00K | 686.00K | 1.55M | 469.84M |
| Foreign Exchange rate Adjustments | -149.00K | 1.05M | 335.00K | 2.73M | -1.61M |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -98.26M | -87.06M | -75.36M | -55.57M | 421.01M |